Emily Charrier

ORCID: 0000-0001-6143-509X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cancer Research and Treatments
  • T-cell and B-cell Immunology
  • Hematopoietic Stem Cell Transplantation
  • Herpesvirus Infections and Treatments
  • Lung Cancer Research Studies
  • IL-33, ST2, and ILC Pathways
  • Cancer Cells and Metastasis
  • Immune cells in cancer
  • Autoimmune and Inflammatory Disorders Research
  • Cytomegalovirus and herpesvirus research
  • Immune Response and Inflammation
  • Reproductive System and Pregnancy
  • SARS-CoV-2 and COVID-19 Research
  • RNA Interference and Gene Delivery
  • Nanoplatforms for cancer theranostics
  • Immunodeficiency and Autoimmune Disorders
  • Pancreatic function and diabetes
  • Inflammasome and immune disorders
  • CRISPR and Genetic Engineering
  • Toxoplasma gondii Research Studies
  • Parvovirus B19 Infection Studies

University of Geneva
2020-2024

Swiss Cancer Center Léman
2024

Université Claude Bernard Lyon 1
2013-2023

Inserm
2014-2023

École Normale Supérieure de Lyon
2014-2023

Centre National de la Recherche Scientifique
2016-2023

University Hospital of Geneva
2021-2023

Centre International de Recherche en Infectiologie
2014-2023

Université de Lyon
2023

Hospices Civils de Lyon
2013-2021

Trail+DX5−Eomes− natural killer (NK) cells arise in the mouse fetal liver and persist adult liver. Their relationships with Trail−DX5+ NK remain controversial. We generated a novel Eomes-GFP reporter murine model to address this question. found that Eomes− are not precursors of classical Eomes+ but rather constitute distinct lineage innate lymphoid cells. strictly dependent on both T-bet IL-15, similarly NKT observed that, liver, expression progenitors represses Eomes development...

10.1084/jem.20131560 article EN cc-by-nc-sa The Journal of Experimental Medicine 2014-02-10

Abstract The liver is the largest gland in human body and functions as an innate immune organ. Liver macrophages called Kupffer cells (KC) constitute group of body. Innate responses involving KC represent first line defense against pathogens liver. Human monocyte-derived have been used to characterize inflammasome that lead release proinflammatory cytokines IL-1β IL-18, but it has not yet determined whether contain functional inflammasomes. We show, our knowledge for time, express genes...

10.4049/jimmunol.1502301 article EN The Journal of Immunology 2016-05-26

Lymphoid differentiation and activation critically depend on cytokine stimulation the interleukin-7 (IL-7) signaling in particular. Although it has been demonstrated that IL-7 may play a role natural killer (NK) cell maturation, effect of mature human NK cells not studied. We, therefore, investigated expression functional activity IL-7Ralpha populations from adult blood. In this article, we demonstrate is specifically expressed CD56bright noncytotoxic cytokine-producing subset. Importantly,...

10.1097/cji.0b013e3181cd872d article EN Journal of Immunotherapy 2010-04-09

Physiological modulation of the immune system is required for foetal tolerance during pregnancy. However, this regulation might lead to impaired self-defence against pathogens. Indeed, pregnant women are more susceptible newly encountered viruses comparing non-pregnant women, as exemplified by prevalence severe complications in infected with pandemic influenza virus 2009. Plasmacytoid dendritic cells (pDCs) specialized that recognise viral antigens and initiate both innate adaptive...

10.3109/08820139.2012.682243 article EN Immunological Investigations 2012-05-17

Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that still incurable. Natural Killer (NK) can recognize and kill MM in vitro, limit growth vivo. Previous reports have shown NK cell function impaired during progression suggested treatment with immunomodulatory drugs (IMIDs) such as lenalidomide (LEN) could enhance it. However, the effects IMIDs on been tested mostly vitro or preclinical models supporting evidence their effect vivo patients lacking. Here, we monitored...

10.3389/fimmu.2018.00704 article EN cc-by Frontiers in Immunology 2018-04-13

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, characterized by a high degree of intertumoral heterogeneity. However, feature GBM microenvironment hypoxia, which can promote radio- chemotherapy resistance, immunosuppression, angiogenesis, stemness. We experimentally defined adaptations to physiologically relevant oxygen gradients, we assessed their modulation metabolic drug metformin. directly exposed human cell lines hypoxia (1% O2) physioxia (5% O2)....

10.3390/biology9090264 article EN cc-by Biology 2020-09-02

Umbilical cord blood (UCB) is increasingly used as a source of hematopoietic progenitor cells to treat variety disorders. UCB transplant associated with comparatively reduced incidence graft-versus-host disease, robust graft versus leukemia effect, and relatively high opportunistic infections, three processes in which donor-derived T lymphocytes are known be predominantly involved. To examine the differential functionality cells, CD8(+) specific for melanoma-associated HLA-A2-restricted...

10.4049/jimmunol.0902613 article EN The Journal of Immunology 2010-06-12

CMV and varicella zoster virus (VZV) are significant causes of morbidity mortality following umbilical cord blood transplantation (UCBT). However, the kinetics reconstitution protective potential antiviral cell-mediated immune responses UCBT remain poorly characterized. In this study, CMV- VZV-specific T cell was assessed using IFN-γ ELISPOT in 28 children who underwent to treat hematological or inherited disorders. Barely detectable first 3 mo posttransplantation, were observed 30.4% 40.3%...

10.4049/jimmunol.1201759 article EN The Journal of Immunology 2012-10-04

Despite many promising results obtained in previous preclinical studies, the clinical development of encapsulated cell technology (ECT) for delivery therapeutic proteins from macrocapsules is still limited, mainly due to lack an allogeneic line compatible with application humans. In our work, we generated immortalized human myoblast specifically tailored macroencapsulation. present report, characterized myoblasts and described engineering process required functional including a cytokine,...

10.1016/j.omtm.2022.07.017 article EN cc-by Molecular Therapy — Methods & Clinical Development 2022-08-02

NK cells are cytotoxic lymphocytes displaying strong antimetastatic activity. Mouse models and in vitro studies suggest a prominent role of the mechanistic target rapamycin (mTOR) kinase control cell homeostasis antitumor functions. However, mTOR inhibitors used as chemotherapies several cancer settings. The impact such treatments on patients' is unknown. We thus performed immunophenotyping circulating from metastatic breast patients treated with inhibitor everolimus over three-month period....

10.4049/jimmunol.2001215 article EN The Journal of Immunology 2021-04-30

Plasmacytoid dendritic cells (pDCs) initiate both innate and adaptive immune responses, making them attractive targets for post-transplantation immunotherapy, particularly after cord blood transplantation (CBT). Toll-like receptor (TLR) agonists are currently studied pDC stimulation in various clinical settings. Their efficacy depends on number functionality, which unknown CBT. We performed a longitudinal study of reconstitution children who underwent bone marrow (BMT) single-unit Both CBT...

10.1016/j.bbmt.2014.06.007 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2014-08-13

e18005 Background: MVX-ONCO-1 is an active, personalized cancer immunotherapy combining irradiated autologous tumor cells and encapsulated, genetically engineered allogeneic producing GM-CSF. The immunostimulant cytokine released locally in a sustained manner over one week at the immunization site. All types are potential candidates more than 40 patients have been treated two clinical trials. Here we report data on all HNSCC treated, as of 31 st January 2021. Methods: Eleven (11) with...

10.1200/jco.2021.39.15_suppl.e18005 article EN Journal of Clinical Oncology 2021-05-20

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory condition that occurs in patients with genetic defects of cytotoxicity (familial HLH [FHL]) or secondary to other immunological disorders such as juvenile idiopathic arthritis. characterized by elevated levels serum IL-18 and cytokines. Moreover, novel clinical entity has been recently identified which constitutive NLRC4 inflammasome activation leads HLH. Altogether, these observations suggest central event the...

10.4049/jimmunol.1701628 article EN The Journal of Immunology 2018-04-25

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with recurrences. Therefore, finding vaccine for this virus became priority the scientific community. The SARS-CoV-2 spike protein been described as keystone viral entry into cells and effective immune protection against is elicited by protein. Consequently, many commercialized vaccines focus on require use of an optimal adjuvant during vaccination. Granulocyte-macrophage colony-stimulating factor...

10.3390/vaccines9050484 article EN cc-by Vaccines 2021-05-10

Abstract Over two decades, most cancer vaccines failed clinical development. Key factors may be the lack of efficient priming with tumor-specific antigens and strong immunostimulatory signals. MVX-ONCO-1, a personalized cell-based immunotherapy, addresses these critical steps utilizing clinical-grade material to replicate successful combination seen in experimental models: inactivated patient’s own tumor cells, providing widest cancer-specific antigen repertoire standardized, sustained,...

10.1158/2767-9764.crc-24-0150 article EN cc-by Cancer Research Communications 2024-07-23
Coming Soon ...